Argenx Se ARGX
NASDAQ ARGX
$1,033.15 -20.31 (-1.93%)
At close: Sep 4, 2026 · 4:00 PM EDT

Argenx Se (ARGX) Accumulated Expenses (2016 - 2017)

Argenx Se's (ARGX) quarterly Accumulated Expenses came in at $1099.5 in Q2 2017, up 1.84% quarter-over-quarter from $1079.7 in Q4 2016.

Analysis

Argenx Se (ARGX) Accumulated Expenses (2016 - 2017) Analysis & Trends

Argenx Se (ARGX) has reported Accumulated Expenses for 2 consecutive years, with $1099.5 the latest figure, recorded in Q2 2017.

  • For the quarter ending Q2 2017, Accumulated Expenses changed N/A year-over-year to $1099.5; the trailing twelve-month figure through Jun 2017 stood at $1099.5 (changed N/A YoY), and the FY2016 full-year result was $1107.1, changed N/A from the prior year.
  • Accumulated Expenses advanced to $1099.5 in Q2 2017 per ARGX's latest filing, from $1079.7 in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $1099.5 in Q2 2017 and bottomed at $1079.7 in Q4 2016.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 236.37 Bn 222.38 Bn 7.24 Bn
2 Gilead Sciences 187.38 Bn 184.12 Bn 6.22 Bn
3 Vertex Pharmaceuticals 138.36 Bn 130.51 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 85.09 Bn 77.10 Bn 3.93 Bn
5 Argenx Se 63.93 Bn 58.75 Bn 1.37 Bn
6 Moderna 58.07 Bn 52.94 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 35.59 Bn 32.28 Bn 992.69 Mn
8 Biogen 32.63 Bn 31.34 Bn 1.96 Bn
9 Insmed 27.57 Bn 26.41 Bn 358.27 Mn
10 BioNTech SE 26.24 Bn 12.58 Bn 10.00 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2017 1,099.55
Dec 31, 2016 1,079.72